Author:
Stillo Francesco,Ruggiero Federica,Mattassi Raul,Amato Bruno,Compagna Rita
Abstract
Aims: Vascular anomalies (VA) represent a heterogeneous and rare group of pathologies. Ethanol is considered the gold standard in endovascular embolization procedures, but its use exposes to the risk of major complications. Glubran-2 is a new glue agent, used mainly for catheter-based cerebral embolization. Our study reported preliminary experiences with a group of 13 patients treated for intramuscular VA of limbs with Glubran-2 solution by venous retrograde percutaneous embolization.
Methods: Through an Angiographic CT/MRI we selected 13 adult patients (6 males, 7 females), seven with limb AVMs and six with limb VM, all intramuscular. All patients reported pain and functional limitation as presenting symptoms. Glubran-2 was injected under fluoroscopic guidance through multiple percutaneous punctures, to cover the entire extension of the lesion.
Results: In the 6-month follow-up, all patients reported pain reduction, rapid recovery of function, favourable post-operative course and absence of major complications. Angio-RMI control was performed in all patients. It showed Glubran-2 in place and the exclusion of the malformation. Percutaneous retrograde embolization with Glubran-2 permanently excluded muscle malformations from circulation: only one embolization procedure was, in 12 of 13 patients, sufficient for a complete and definitive treatment. Rapid polymerization of Glubran-2 glue, after its injection, cancelled the risk of pulmonary embolisms and skin necrosis. Secondary surgical removal was never necessary to complete treatment of these deep muscle malformations.
Conclusions: This study showed that the percutaneous embolization technique with Glubran-2 glue can be considered favorable in the treatment of the VA of the limbs for its easier handling and promising outcome.
Reference22 articles.
1. Hassanein AH, Mulliken JB, Fishman SJ, Greene AK. Evaluation of terminology for vascular anomalies in current literature. Plast Reconstr Surg 2011; 127(01): 347-351. https://doi.org/10.1097/PRS.0b013e3181f95b83
2. Wassef M, Blei F, Adams D, et al. Vascular anomalies classification: recommendations from the International Society for the Study of Vascular Anomalies. Pediatrics 2015; 136(01): e203-e214. https://doi.org/10.1542/peds.2014-3673
3. Stillo F, Baraldini V, Dalmonte P, El Hachem M, Mattassi R, Vercellio G, et al. Vascular Anomalies Guidelines by the Italian Society for the study of Vascular Anomalies (SISAV). International Angiology 2015; 34(2 Suppl 1): 1-45.
4. Gloviczki P, Duncan A, Kalra M, et al. Vascular malformations: an update. Perspect Vasc Surg Endovasc Ther 2009; 21: 133-148. https://doi.org/10.1177/1531003509343019
5. Mattassi R. Surgical treatment of congenital arteriovenous defects. Int Angiol 1990; 9: 196-202.